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ABSTRACT 
 
Objective: Stroke is the second most common cause of death in most countries.1 In South 
Africa, which has a population undergoing demographic and epidemiological transition, stroke 
is the third most common cause of death.2  Platelet response to therapeutic doses is not 
uniform, although aspirin remains an essential part of treatment. Some patients exhibit aspirin 
resistance and develop secondary thrombotic events. It was decided to determine the 
prevalence of aspirin resistance and/or platelet hypersensitivity, as determined by platelet 
aggregometry, in sixty Caucasian patients who have suffered one or more strokes and/or 
Transient Ischaemic Attacks (TIAs) as compared with sixty control subjects.  
Methods: Aspirin resistance was determined by platelet aggregation (>20%) to one or more of 
the four agonists, namely arachidonic acid (1.5mM), adrenaline (0.05µg/ml), collagen 
(0.2µg/ml) or ADP (0.1x10-5M).  
Results: Two patients demonstrated ‘complete aspirin resistance’ (non-responder to aspirin) 
with resistance to arachidonic acid (high concentration) noted. Three patients demonstrated 
‘partial aspirin resistance’ (semi-responder to aspirin). One control subject showed ‘complete 
aspirin resistance’. There is a 1.67% chance of a control subject being resistant to aspirin in a 
general South African Caucasian population. A history of prior stroke or transient ischaemic 
attack was associated with a statistically significant increase in risk of aspirin resistance with 
an odds ratio of 5.36. 
Conclusion: These results essentially concur with those of the studied literature in showing an 
8.3% prevalence (statistically significant) of aspirin resistance (complete and partial) in South 
 vi 
African Caucasian patients with previous atherothrombotic cerebrovascular events i.e.CVAs 
and/or TIAs. The current study shows an increased prevalence of aspirin resistance in people 
who have had prior strokes / TIAs and raises the question whether people who have had these 
events are somehow predisposed to vascular events or indeed recurrent vascular events.    
‘Aspirin resistant’ patients or ‘poor responders’ to aspirin must be considered at heightened 
risk of atherothrombotic events and laboratory monitoring of antiplatelet therapy may become 
clinically useful. 
 
 vii 
ACKNOWLEDGEMENTS 
 
1. Many thanks to Professor Barry Jacobson, Head of Clinical Haematology, Department of 
Molecular Medicine and Haematology, National Health Laboratory Service (NHLS) and the 
Faculty of Health Sciences, University of the Witwatersrand, for his continuous support in this 
project. His enthusiasm, patience, effort and sound practical advice have been an inspiration to 
me both in this research report, international publication and in my daily dealings with 
Haematology (both in the laboratory and with regard to patients).  
 
2. I wish to thank Professor Myles Connor, previously a consultant Neurologist from the 
Department of Neurosciences, Faculty of Health Sciences, University of the Witwatersrand, 
for his insight, guidance and assistance with the study and the international publication.  
 
3. Many thanks also to Professor Piet Becker of the Biostatistics Unit, Medical Research 
Council of South Africa (SAMRC) and School of Therapeutic Sciences, University of the 
Witwatersrand, for his help with the statistical analysis of the data.  
 
4. The source of funding was from the South African Society of Thrombosis and Haemostasis 
(SASTH) Research Fund. 
 viii
 
TABLE OF CONTENTS         PAGE 
  
DECLARATION          ii 
DEDICATION          iii 
PUBLICATIONS AND PRESENTATIONS ARISING FROM THIS STUDY  iv 
ABSTRACT           v 
ACKNOWLEDGEMENTS         vii 
TABLE OF CONTENTS         viii 
LIST OF TABLES          xi 
LIST OF FIGURES         xii 
ABBREVIATIONS          xiii 
  
1. INTRODUCTION AND LITERATURE REVIEW  
1.1 The haemostatic response                                        1 
1.1.1 Vasoconstriction                                                                                             1 
1.1.2 Primary haemostasis and platelet reactions  2 
1.1.3 Stabilisation of the platelet plug by fibrin  4 
1.2 Stroke  5 
1.3 Antiplatelet agents 7 
1.4  Aspirin 
1.5        Aspirin resistance 
10 
11 
1.6 Platelet aggregometry testing 13 
 ix
  
2. STUDY OBJECTIVE  16 
  
3. STUDY POPULATIONS, MATERIALS AND METHODS  
3.1 Case selection 16 
3.2 Control selection 17 
3.3 Laboratory methods  18 
3.3.1    Principle 18 
3.3.2 Instrument description 18 
3.3.3 Patient preparation and specimen collection 20 
3.3.4 Preparation of platelets 20 
3.3.5 Aggregating agents (agonists) 21 
3.3.6 Stepwise procedure and interpretation of platelet aggregation curves 22 
3.3.7 Comments and limitations 23 
3.4 Statistical analysis 24 
3.5 Ethics 25 
  
4. RESULTS  
4.1 Patient results 26 
4.2 Control results 28 
  
5. DISCUSSION 29 
  
 x
 
 
  
6. CONCLUSION 35 
  
7. APPENDICES  
 Appendix A: Copy of the Ethics Clearance Certificate  
               Appendix B: Results on which statistical analysis was performed  
                                     (raw data).  
36 
37 
  
8. REFERENCES 40 
  
 xi
LIST OF TABLES 
 
Table          Page 
 
Table 3.1 High and low concentrations of agonists.   22 
 xii
LIST OF FIGURES 
 
Figure           Page 
 
Figure 1.1 The interaction of blood vessels, blood coagulation and platelet  2 
in haemostasis.  
 
Figure 1.2 Primary haemostasis.       3 
 
Figure 1.3 The production of prostacyclin and thromboxane.   4 
 
Figure 1.4 Sites of action of antiplatelet drugs.     12 
 
Figure 3.1  APACT 2 ON Helena Aggregometer ™.    19 
 
Figure 3.2 APACT 2 ON Helena Aggregometer ™ - Top View.  19 
 
Figure 3.3 Platelet aggregation studies.      21 
 
Figure 4.1  Trace from a patient with ‘partial aspirin resistance’.  27 
 
Figure 4.2 Trace from a control subject with ‘complete aspirin resistance’.  28 
 
 
 xiii
ABBREVIATIONS 
 
AA  Arachidonic Acid 
ADP  Adenosine Diphosphate 
AMP  Adenosine Monophosphate 
APACT2 Automated Platelet Aggregation  
ATP  Adenosine Triphosphate 
Ca2+  Calcium  
cAMP  cyclic Adenosine Monophosphate 
CI  Confidence Interval  
COX  Cyclooxygenase 
CT  Computed Tomography 
CVA  Cerebro-Vascular Accident 
FBC  Full Blood Count 
GP  Glycoprotein  
HIV  Human Immunodeficiency Virus 
LTA  Light Transmission Aggregometry 
MI                   Myocardial Infarct 
MRI  Magnetic Resonance Imaging 
NF-ĸB             Nuclear Factor kappa-light-chain-enhancer of activated B cells  
NSAID            Non-Steroidal Anti-Inflammatory Drug 
PGI2  Prostaglandin Inhibitor  
PPI                  Proton Pump Inhibitors 
PPP  Platelet Poor Plasma 
 xiv
PRP  Platelet Rich Plasma 
SOP  Standard Operating Procedure 
TIA  Transient Ischaemic Attack  
tPA  tissue Plasminogen Activator 
TTP                 Thrombotic Thrombocytopenic Purpura 
TxA2  Thromboxane A2 
TxB2  Thromboxane B2 
VWF  Von Willebrand Factor 
 
 
